Is Barinthus Biotherapeutics plc (BRNS) a Buy, Sell, or Hold?
Barinthus Biotherapeutics plc
NASDAQ:BRNS
$0.6122 USD
$0.0 (0.36%)
- Volume
- 26.66K
- Average Volume
- 69.38K
- Market Capitalization
- $25.01M
- P/E Ratio
- -0.47
- Dividend Yield
- 0.00%
- Price Target
- $3.00
- Year High
- $2.92
- Year Low
- $0.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.05
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | William James Enright |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BRNS |
| CUSIP | 91864C107 |
| CIK | 0001828185 |
| Web | https://www.barinthusbio.com |
| Phone | 44 1865 818 808 |
| Currency | USD |
| Employees | 14 |
| Country | GB |
Liquidity
| Debt-to-Equity Ratio | 0.17 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.05 |
| Quick Ratio | 6.05 |
| Cash Ratio | 5.60 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.89 |
| Price / Cash Flow | -0.69 |
| Price / Book | 0.38 |
Price Target and Rating
| Average Stock Price Forecast | $3.00 |
| High Stock Price Forecast | $3.00 |
| Low Stock Price Forecast | $3.00 |
| Forecast Upside/Downside | -79.59% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 4 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.64 |
| Trailing P/E Ratio | -0.47 |
| PEG Ratio | -0.03 |
| P/E Growth | -0.03 |
| Net Income | $-66.58M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -63.87% |
| Return on Assets | -56.74% |
Financials Score
| AltmanZ Score | -5.22 |
| Piotroski Score | 1.00 |
| Working Capital | 60.66M |
| Total Assets | 92.14M |
| Ebit | -52.69M |
| Market Cap | 24.92M |
| Total Liabilities | 25.66M |
Poll Results
About Barinthus Biotherapeutics plc (NASDAQ:BRNS) Stock
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI p ... latform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.
Are KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?
2026-05-12 02:54:00
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
2026-05-11 12:08:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate,.
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
2026-04-30 07:30:00
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended March 31, 2026, and provided an overview of the Company's corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies that promote immune tolerance with curative potential.
Frequently Asked Questions
-
What is the current Barinthus Biotherapeutics plc (BRNS) stock price?
-
Barinthus Biotherapeutics plc(NASDAQ:BRNS) stock price is $0.6122 in the last trading session. During the trading session, BRNS stock reached the peak price of $2.92 while $0.512 was the lowest point it dropped to. The percentage change in BRNS stock occurred in the recent session was 0.36% while the dollar amount for the price change in BRNS stock was $0.0.
-
BRNS's industry and sector of operation?
-
The NASDAQ listed BRNS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BRNS?
-
Leon Hooftman | Chief Medical Officer
William J. Enright | Chief Executive Officer & Director
Douglas J. Swirsky | CFO & Principal Accounting Officer
|
| -
How many employees does BRNS have?
-
Number of BRNS employees currently stands at 14. BRNS operates from Zeus Building, Didcot, OX OX11 0DF, GB.
-
Link for BRNS official website?
-
Official Website of BRNS is: https://www.barinthusbio.com
-
How do I contact BRNS?
-
BRNS could be contacted at phone #44 1865 818 808 and can also be accessed through its website. BRNS operates from Zeus Building, Didcot, OX OX11 0DF, GB.
-
How many shares of BRNS are traded daily?
-
The average number of BRNS shares traded daily for last 3 months was 69.38K.
-
What is the market cap of BRNS currently?
-
The market value of BRNS currently stands at $25.01M with its latest stock price at $0.6122